An observational study in Peripheral Arterial Disease, Critical Limb Ischemia and Critical Lower Limb Ischemia, sponsored by University Hospitals Cleveland Medical Center. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by University Hospitals Cleveland Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Chronic Limb-Threatening Ischemia with a site in United States — 13 open to participants now, 20 under way, 2 of them phase 3. Chronic Limb-Threatening Ischemia · United States.
Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, this one is the 17th largest by planned enrollment of the 19 observational ones that give a count, is one of 4 that started in 2025, is one of 19 observational ones, reaches primary completion later than 15 of the 19 other live ones, and was the 102nd registered.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
Browse Chronic Limb-Threatening Ischemia studies →13 of the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States are open now. Recruiting first, the newest first:
Mercator MedSystems, Inc. · Sites in United States
Ages 18+
R3 Vascular Inc. · Sites in United States
Ages 18+
Medistim ASA · Sites in United States
Ages 18+
Versono Medical Ltd · Sites in United States
Ages 18–85
Cagent Vascular LLC · Sites in United States
Ages 19+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 19 · Phase 3 10 · Phase 4 3
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Median enrollment 38 across the 82 interventional studies, 102 across the 19 observational. Of the 69 that completed or were terminated, 25 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 105 have an industry lead sponsor. The 10 most frequent:
University Hospitals Cleveland Medical Center is the lead sponsor of 296 studies on the registry; 46 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 30 (83%) have results posted.
University Hospitals Cleveland Medical Center has 3 studies filed under Chronic Limb-Threatening Ischemia — fewer than ten, so there is no comparison to draw.
9 of the studies in Chronic Limb-Threatening Ischemia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT06492733Versono Medical LtdFastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW | 2026-11 |
| NCT05830721Johns Hopkins UniversityContinuous Compartment Pressure Monitoring for Compartment Syndrome in VA-ECMO Patients | 2026-12 |
| NCT05145478Yale UniversityCRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions | 2026-12-31 |
| NCT06311773Aveera Medical, Inc.Pivotal Trial of the Boomerang Catheter for pDVA | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 105 studies in Chronic Limb-Threatening Ischemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure.
The main question this study aims to answer is:
- Are temperature measurements from a forward looking infrared (FLIR) camera of the lower extremity useful in predicting outcome of revascularization procedures?
This is a preliminary prospective observational study measuring change in lower extremity temperature in response to revascularization procedure.
Patients with lower extremity PAD will be seen in office pre-intervention. Consent to participate in the TIC study will be acquired at this point. Patients will be given a physical copy of their consent form at the time consent is obtained. During this initial visit or subsequent pre-procedural office visit, the smartphone-based thermal camera will be utilized to measure the temperature of the lower extremity foot, ankle, and leg at the plantar, dorsal, and lateral distributions. Comorbidities and demographic factors will be documented from medical records at this time as well.
Data will be gathered at a consistent location to minimize impact of room temperature on measurements.
Patients will then undergo scheduled revascularization with the interventionist.
Post-intervention pictures will be taken immediately after revascularization.
Patients will then be seen again by the research team for follow-up thermal camera imaging, 1 week post-intervention, and weekly post intervention for at least 1 month but up to 6 months.
Thermal measurements will be correlated with intra-op imaging and clinical outcomes in data analysis.
359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.
This study's planned enrollment of 25 is below the median of 111 across 104 observational studies indexed under Chronic Limb-Threatening Ischemia.
Browse Chronic Limb-Threatening Ischemia studies →University Hospitals Cleveland Medical Center is the lead sponsor of 296 studies on the registry; 46 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 30 (83%) have results posted.
Compared within Chronic Limb-Threatening Ischemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Arterial Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
People between ages 18 and 99 years with lower extremity peripheral artery disease with a planned endovascular intervention.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Temperature measurements will be taken of the lower limb using the FLIR camera and correlated with other aspects of each patient.
Device: FLIR One Pro LT
Thermal imaging camera used to measure temperatures of the lower limb.
Change in ABI
Ankle brachial index will be taken before and after intervention and correlated with thermal readings from FLIR.
Time frame: Up to 90 days before revascularization; Up to 1 year after revascularization
Major amputations
Any associated amputations the subject had after revascularization
Time frame: Up to 1 year after revascularization
Major revascularizations post-initial intervention
Any revascularization procedures done after the initial revascularization
Time frame: Up to 1 year after revascularization
Mortality
Subject deaths during the length of the study
Time frame: Up to 1 year after revascularization
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.
Of 47 non-industry observational studies under Chronic Limb-Threatening Ischemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 60. This study's planned 30 months is below that.
Counting every sponsor, half of 53 studies reached it within 34 months; a quarter within 22 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chronic Limb-Threatening Ischemia →
University Hospitals Cleveland Medical Center →